Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
Status:
Completed
Trial end date:
2012-04-03
Target enrollment:
Participant gender:
Summary
This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in
preventing skeletal complications in multiple myeloma participants who have been on an
intravenous (IV) bisphosphonate for about one to two years.